Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy

Nozomi Hayakawa, Kazuhiro Matsumoto, Atsuko Sato, Hirofumi Sakamoto, Taisuke Ezaki, Takahiro Maeda, Akiharu Ninomiya, So Nakamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the efficacy of tegafur-uracil (UFT) administration as a fourth-line therapy in patients with castration-resistant prostate cancer (CRPC) who had already received combined androgen blockade (CAB) therapy (first-line), alternative antiandrogen therapy (second-line), and estramustine phosphate sodium hydrate (EMP) therapy (third-line), in order to determine who would benefit from UFT therapy. Methods: UFT was administered at a daily dose of 300 mg/m2 to 26 patients, and the response to UFT 4 weeks after its induction and its toxicity were evaluated. Results: A reduction in the serum prostate-specific antigen (PSA) value was observed in 12 patients (46.2 %), while two cases (7.7 %) achieved more than 50 % reduction in PSA. Two patients (7.7 %) required discontinuation of UFT administration because of side effects (grade 2 exanthema in one patient and grade 2 nausea in one patient). A PSA response to UFT was observed, especially in patients older than 75 years and/or whose Gleason score was 8 or less. Conclusions: Our data indicate that UFT administration as a fourth-line therapy was tolerable and effective to some degree in patients with CRPC who had already received CAB therapy, alternative antiandrogen therapy, and EMP therapy. It can be used, even in patients aged more than 75 years old, without any loss of efficacy or effect on their activities of daily life, and can be regarded as a treatment option for patients with advanced prostate cancer.

Original languageEnglish
Pages (from-to)1123-1129
Number of pages7
JournalInternational Urology and Nephrology
Volume46
Issue number6
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Estramustine
Tegafur
Androgen Antagonists
Uracil
Castration
Complementary Therapies
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Androgens
Neoplasm Grading
Exanthema
Nausea

Keywords

  • CRPC
  • Gleason score
  • Prostate cancer
  • PSA
  • UFT

ASJC Scopus subject areas

  • Nephrology
  • Urology
  • Medicine(all)

Cite this

Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy. / Hayakawa, Nozomi; Matsumoto, Kazuhiro; Sato, Atsuko; Sakamoto, Hirofumi; Ezaki, Taisuke; Maeda, Takahiro; Ninomiya, Akiharu; Nakamura, So.

In: International Urology and Nephrology, Vol. 46, No. 6, 2014, p. 1123-1129.

Research output: Contribution to journalArticle

@article{876aa62a7770402186eba010261a3f47,
title = "Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy",
abstract = "Purpose: The purpose of this study was to evaluate the efficacy of tegafur-uracil (UFT) administration as a fourth-line therapy in patients with castration-resistant prostate cancer (CRPC) who had already received combined androgen blockade (CAB) therapy (first-line), alternative antiandrogen therapy (second-line), and estramustine phosphate sodium hydrate (EMP) therapy (third-line), in order to determine who would benefit from UFT therapy. Methods: UFT was administered at a daily dose of 300 mg/m2 to 26 patients, and the response to UFT 4 weeks after its induction and its toxicity were evaluated. Results: A reduction in the serum prostate-specific antigen (PSA) value was observed in 12 patients (46.2 {\%}), while two cases (7.7 {\%}) achieved more than 50 {\%} reduction in PSA. Two patients (7.7 {\%}) required discontinuation of UFT administration because of side effects (grade 2 exanthema in one patient and grade 2 nausea in one patient). A PSA response to UFT was observed, especially in patients older than 75 years and/or whose Gleason score was 8 or less. Conclusions: Our data indicate that UFT administration as a fourth-line therapy was tolerable and effective to some degree in patients with CRPC who had already received CAB therapy, alternative antiandrogen therapy, and EMP therapy. It can be used, even in patients aged more than 75 years old, without any loss of efficacy or effect on their activities of daily life, and can be regarded as a treatment option for patients with advanced prostate cancer.",
keywords = "CRPC, Gleason score, Prostate cancer, PSA, UFT",
author = "Nozomi Hayakawa and Kazuhiro Matsumoto and Atsuko Sato and Hirofumi Sakamoto and Taisuke Ezaki and Takahiro Maeda and Akiharu Ninomiya and So Nakamura",
year = "2014",
doi = "10.1007/s11255-013-0634-5",
language = "English",
volume = "46",
pages = "1123--1129",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy

AU - Hayakawa, Nozomi

AU - Matsumoto, Kazuhiro

AU - Sato, Atsuko

AU - Sakamoto, Hirofumi

AU - Ezaki, Taisuke

AU - Maeda, Takahiro

AU - Ninomiya, Akiharu

AU - Nakamura, So

PY - 2014

Y1 - 2014

N2 - Purpose: The purpose of this study was to evaluate the efficacy of tegafur-uracil (UFT) administration as a fourth-line therapy in patients with castration-resistant prostate cancer (CRPC) who had already received combined androgen blockade (CAB) therapy (first-line), alternative antiandrogen therapy (second-line), and estramustine phosphate sodium hydrate (EMP) therapy (third-line), in order to determine who would benefit from UFT therapy. Methods: UFT was administered at a daily dose of 300 mg/m2 to 26 patients, and the response to UFT 4 weeks after its induction and its toxicity were evaluated. Results: A reduction in the serum prostate-specific antigen (PSA) value was observed in 12 patients (46.2 %), while two cases (7.7 %) achieved more than 50 % reduction in PSA. Two patients (7.7 %) required discontinuation of UFT administration because of side effects (grade 2 exanthema in one patient and grade 2 nausea in one patient). A PSA response to UFT was observed, especially in patients older than 75 years and/or whose Gleason score was 8 or less. Conclusions: Our data indicate that UFT administration as a fourth-line therapy was tolerable and effective to some degree in patients with CRPC who had already received CAB therapy, alternative antiandrogen therapy, and EMP therapy. It can be used, even in patients aged more than 75 years old, without any loss of efficacy or effect on their activities of daily life, and can be regarded as a treatment option for patients with advanced prostate cancer.

AB - Purpose: The purpose of this study was to evaluate the efficacy of tegafur-uracil (UFT) administration as a fourth-line therapy in patients with castration-resistant prostate cancer (CRPC) who had already received combined androgen blockade (CAB) therapy (first-line), alternative antiandrogen therapy (second-line), and estramustine phosphate sodium hydrate (EMP) therapy (third-line), in order to determine who would benefit from UFT therapy. Methods: UFT was administered at a daily dose of 300 mg/m2 to 26 patients, and the response to UFT 4 weeks after its induction and its toxicity were evaluated. Results: A reduction in the serum prostate-specific antigen (PSA) value was observed in 12 patients (46.2 %), while two cases (7.7 %) achieved more than 50 % reduction in PSA. Two patients (7.7 %) required discontinuation of UFT administration because of side effects (grade 2 exanthema in one patient and grade 2 nausea in one patient). A PSA response to UFT was observed, especially in patients older than 75 years and/or whose Gleason score was 8 or less. Conclusions: Our data indicate that UFT administration as a fourth-line therapy was tolerable and effective to some degree in patients with CRPC who had already received CAB therapy, alternative antiandrogen therapy, and EMP therapy. It can be used, even in patients aged more than 75 years old, without any loss of efficacy or effect on their activities of daily life, and can be regarded as a treatment option for patients with advanced prostate cancer.

KW - CRPC

KW - Gleason score

KW - Prostate cancer

KW - PSA

KW - UFT

UR - http://www.scopus.com/inward/record.url?scp=84903591365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903591365&partnerID=8YFLogxK

U2 - 10.1007/s11255-013-0634-5

DO - 10.1007/s11255-013-0634-5

M3 - Article

C2 - 24356920

AN - SCOPUS:84903591365

VL - 46

SP - 1123

EP - 1129

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 6

ER -